Expert Opinion on Therapeutic Targets最新文献_第6页

Pathways and targeting avenues of BRAF in non-small cell lung cancer. 非小细胞肺癌中 BRAF 的作用途径和靶向途径。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-07-01 Epub Date: 2024-07-04 DOI: 10.1080/14728222.2024.2374742

Evgeny N Imyanitov, Natalia V Mitiushkina, Ekatherina Sh Kuligina, Vladislav I Tiurin, Aigul R Venina

{"title":"Pathways and targeting avenues of BRAF in non-small cell lung cancer.","authors":"Evgeny N Imyanitov, Natalia V Mitiushkina, Ekatherina Sh Kuligina, Vladislav I Tiurin, Aigul R Venina","doi":"10.1080/14728222.2024.2374742","DOIUrl":"10.1080/14728222.2024.2374742","url":null,"abstract":"Introduction: BRAF is a serine-threonine kinase implicated in the regulation of MAPK signaling cascade. BRAF mutation-driven activation occurs in approximately 2-4% of treatment-naive non-small cell carcinomas (NSCLCs). BRAF upregulation is also often observed in tumors with acquired resistance to receptor tyrosine kinase inhibitors (TKIs).Areas covered: This review describes the spectrum of BRAF mutations and their functional roles, discusses treatment options available for BRAF p.V600 and non-V600 mutated NSCLCs, and identifies some gaps in the current knowledge.Expert opinion: Administration of combined BRAF/MEK inhibitors usually produces significant, although often a short-term, benefit to NSCLC patients with BRAF V600 (class 1) mutations. There are no established treatments for BRAF class 2 (L597, K601, G464, G469A/V/R/S, fusions, etc.) and class 3 (D594, G596, G466, etc.) mutants, which account for up to two-thirds of BRAF-driven NSCLCs. Many important issues related to the use of immune therapy for the management of BRAF-mutated NSCLC deserve further investigation. The rare occurrence of BRAF mutations in NSCLC is compensated by high overall incidence of lung cancer disease; therefore, clinical studies on BRAF-associated NSCLC are feasible.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"613-622"},"PeriodicalIF":4.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pleiotropic CLEC10A: implications for harnessing this receptor in the tumor microenvironment. 多效应 CLEC10A：在肿瘤微环境中利用这种受体的意义。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-07-01 Epub Date: 2024-07-03 DOI: 10.1080/14728222.2024.2374743

Nadia L van der Meijs, Maria Alejandra Travecedo, Filipa Marcelo, Sandra J van Vliet

引用次数: 0

Can we suppress chronic systemic inflammation and postpone age-related diseases by targeting the IgG glycome? 我们能通过靶向IgG糖组来抑制慢性全身炎症并延缓与年龄相关的疾病吗？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2023-11-02 DOI: 10.1080/14728222.2023.2277218

GordAn Lauc

{"title":"Can we suppress chronic systemic inflammation and postpone age-related diseases by targeting the IgG glycome?","authors":"GordAn Lauc","doi":"10.1080/14728222.2023.2277218","DOIUrl":"10.1080/14728222.2023.2277218","url":null,"abstract":"Introduction: Glycans attached to immunoglobulin G are an important regulator of chronic systemic inflammation, one of the key drivers of aging. As people age, glycans that suppress inflammation are being replaced with inflammation-promoting glycans, but the rate of this conversion is highly individual and is affected by genetic, epigenetic, and environmental factors.Areas covered: This review summarizes key studies of IgG glycosylation changes in aging and disease, effects of lifestyle and pharmacological interventions, and mechanisms that regulate IgG glycosylation.Expert opinion: IgG glycome is an important contributor to the process of aging that can be modulated by both lifestyle and pharmacological interventions. Small molecule drugs that would suppress chronic systemic inflammation by modulation of the IgG glycome are still not available, but since gene network regulating IgG glycosylation has been identified and a high-throughput in vitro screening system is available, it is likely that this highly innovative approach to manage chronic systemic inflammation will be developed soon.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"491-499"},"PeriodicalIF":4.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61561694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondria makeover: unlocking the path to healthy longevity. 线粒体改造：开启健康长寿之路。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2023-11-02 DOI: 10.1080/14728222.2023.2277240

Andrés Caicedo, Keshav K Singh

引用次数: 0

Glycoproteins and longevity: an interview with Professor Gordan Lauc. 糖蛋白与长寿：戈尔丹-劳克教授访谈录。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2024-07-05 DOI: 10.1080/14728222.2024.2375809

Ryan Gilroy, Gordan Lauc

引用次数: 0

Curing age-related disease, transforming global medicine. 治愈与年龄相关的疾病，改变全球医学。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2023-11-06 DOI: 10.1080/14728222.2023.2277223

Michael Fossel

引用次数: 0

Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come. 在啮齿类动物中联合使用返老还童干预措施：生物医学老年学的一个里程碑，它的时代已经到来。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2024-03-18 DOI: 10.1080/14728222.2024.2330425

Caitlin J Lewis, Aubrey D de Grey

{"title":"Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come.","authors":"Caitlin J Lewis, Aubrey D de Grey","doi":"10.1080/14728222.2024.2330425","DOIUrl":"10.1080/14728222.2024.2330425","url":null,"abstract":"Introduction: Longevity research has matured to the point where significantly postponing age-related decline in physical and mental function is now achievable in the laboratory and foreseeable in the clinic. The most promising strategies involve rejuvenation, i.e. reducing biological age, not merely slowing its progression.Areas covered: We discuss therapeutic strategies for rejuvenation and results achieved thus far, with a focus on in vivo studies. We discuss the implications of interventions which act on mean or maximum lifespan and those showing effects in accelerated disease models. While the focus is on work conducted in mice, we also highlight notable insights in the field from studies in other model organisms.Expert opinion: Rejuvenation was originally proposed as easier than slowing aging because it targets initially inert changes to tissue structure and composition, rather than trying to disentangle processes that both create aging damage and maintain life. While recent studies support this hypothesis, a true test requires a panel of rejuvenation interventions targeting multiple damage categories simultaneously. Considerations of cost, profitability, and academic significance have dampened enthusiasm for such work, but it is vital. Now is the time for the field to take this key step toward the medical control of aging.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"501-511"},"PeriodicalIF":4.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging AI to identify dual-purpose aging and disease targets. 利用人工智能识别衰老和疾病双重目标。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-06-01 Epub Date: 2023-12-01 DOI: 10.1080/14728222.2023.2288270

Geoffrey Ho Duen Leung, Chun Wai Wong, Frank W Pun, Alex Aliper, Feng Ren, Alex Zhavoronkov

引用次数: 0

The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression. 含胶原蛋白三螺旋重复序列 1 (CTHRC1) 在癌症发展和恶化中的作用。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-05-01 Epub Date: 2024-05-11 DOI: 10.1080/14728222.2024.2349686

Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad

{"title":"The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression.","authors":"Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad","doi":"10.1080/14728222.2024.2349686","DOIUrl":"10.1080/14728222.2024.2349686","url":null,"abstract":"Introduction: Collagen triple helix repeat containing 1 (CTHRC1) is a protein that has been implicated in pro-migratory pathways, arterial tissue-repair processes, and inhibition of collagen deposition via the regulation of multiple signaling cascades. Studies have also demonstrated an upregulation of CTHRC1 in multiple cancers where it has been linked to enhanced proliferation, invasion, and metastasis. However, the understanding of the exact role and mechanisms of CTHRC1 in cancer is far from complete.Areas covered: This review focuses on analyzing the role of CTHRC1 in cancer as well as its associations with clinicopathologies and cancer-related processes and signaling. We have also summarized the available literature information regarding the role of CTHRC1 in tumor microenvironment and immune signaling. Finally, we have discussed the mechanisms associated with CTHRC1 regulations, and opportunities and challenges regarding the development of CTHRC1 as a potential target for cancer management.Expert opinion: CTHRC1 is a multifaceted protein with critical roles in cancer progression and other pathological conditions. Its association with lower overall survival in various cancers, and impact on the tumor immune microenvironment make it an intriguing target for further research and potential therapeutic interventions in cancer.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"419-435"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders. 将炎症小体复合物作为治疗情绪障碍的新策略。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-05-01 Epub Date: 2024-06-18 DOI: 10.1080/14728222.2024.2366872

Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Jason C O'Connor, Antonio Lucio Teixeira

{"title":"Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders.","authors":"Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Jason C O'Connor, Antonio Lucio Teixeira","doi":"10.1080/14728222.2024.2366872","DOIUrl":"10.1080/14728222.2024.2366872","url":null,"abstract":"Introduction: Inflammasome complexes, especially NLRP3, have gained great attention as a potential therapeutic target in mood disorders. NLRP3 triggers a caspase 1-dependent release of the inflammatory cytokines IL-1β and IL-18, and seems to interact with purinergic and kynurenine pathways, all of which are implicated in mood disorders development and progression.Areas covered: Emerging evidence supports NLRP3 inflammasome as a promising pharmacological target for mood disorders. We discussed the available evidence from animal models and human studies and provided a reflection on drawbacks and perspectives for this novel target.Expert opinion: Several studies have supported the involvement of NLRP3 inflammasome in MDD. However, most of the evidence comes from animal models. The role of NLRP3 inflammasome in BD as well as its anti-manic properties is not very clear and requires further exploration. There is evidence of anti-manic effects of P2×R7 antagonists associated with reduction in the brain levels of IL-1β and TNF-α in a murine model of mania. The involvement of other NLRP3 inflammasome expressing cells besides microglia, like astrocytes, and of other inflammasome complexes in mood disorders also deserves further investigation. Preclinical and clinical characterization of NLRP3 and other inflammasomes in mood disorders is needed before considering translational approaches, including clinical trials.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"401-418"},"PeriodicalIF":5.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0